Assembly Biosciences, Inc. (NASDAQ: ASMB) is a Healthcare company (Biotechnology) with a market capitalization of $461M. The Maz Rating grades it against the other companies in its sector.
Assembly Biosciences, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $22.50, Assembly Biosciences, Inc. trades at 27.2x trailing earnings, 6.8x sales and 1.6x book value. Over the last twelve months it generated about $68M of revenue and $17M of net income. It runs a gross margin of 99.9%, an operating margin of -31.8% and a net margin of -16.6%. It shows return on equity of -4.4%, return on invested capital of -7.1% and a free cash flow yield of -8.9%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 12.89. Over the past 52 weeks the share price ranged from $19.20 to $39.71, with a beta of 1.22.
Assembly Biosciences, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 7 Buy and 5 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.